TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00252174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 Active Methylenedioxymethamphetamine
Description: Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stage 1 Low dose Methylenedioxymethamphetamine
Description: Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy conducted with low or active dose MDMA

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy conducted with low or active dose MDMA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy conducted with low or active dose MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2 Active Methylenedioxymethamphetamine
Description: Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg.
Study: NCT04134754

Intervention type: OTHER
Group type: OTHER
Intervention: 6% Carbon dioxide/50% oxygen/balance nitrogen mixture
Description: In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
Study: NCT04507594

Intervention type: PROCEDURE
Intervention: Lung lobectomy OR esophagus cancer resection
Description: Lunge lobectomy (total) Resection of esophagus cancer
Study: NCT00603863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMMU-107 (hPAM4)
Description: 90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
Study: NCT01331759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuropattern™
Description: Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuropattern™
Description: Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
Study: NCT03949023

Intervention type: PROCEDURE
Intervention: Standard of Care Cerebral Angiogram Group
Description: Subjects will undergo the standard of care cerebral angiogram and any intervention(s) (when applicable) that were discussed with their provider, following the standard procedural protocol for the procedure at WFBMC. There are no additional interventions or changes to the planned intervention(s) that will take place by agreeing to participate in the study.~The data collected from this procedure, following the standard of care protocol, will include the following: force of injection of contrast material for each angiographic run (peak pressure associated with injection, duration of peak, and area under pressure curve), volume of contrast utilized, images from the procedure, measurements of vessel diameter at defined distances from the catheter tip utilizing the images, catheter type, any additional device(s) (when applicable) utilized during the procedure, and if spasmolytic agents are utilized (including dose and time of administration).
Study: NCT03253081

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PARENT focused intervention
Description: The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHILD focused intervention
Description: The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
Study: NCT03170440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation location 1
Description: Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nerve stimulation location 1
Description: Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation location 2
Description: Stimulation will be performed using electrodes placed in alternate location.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nerve stimulation location 2
Description: Stimulation will be performed using electrodes placed in alternate location.
Study: NCT03827317

Intervention type: RADIATION
Group type: OTHER
Intervention: [18F]GE-226
Description: \[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.

Intervention type: RADIATION
Group type: OTHER
Intervention: [18F]GE-226
Description: \[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
Study: NCT03898011

Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus

Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
Study: NCT00177216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.
Study: NCT03898011

Intervention type: DRUG
Group type: OTHER
Intervention: Lamictal
Description: Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia

Intervention type: DRUG
Group type: OTHER
Intervention: Lamictal
Description: Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
Study: NCT00177216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
Study: NCT03123198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: DBT is a multimodal comprehensive psychosocial treatment.
Study: NCT05660993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Drug: Nivolumab Schedule: Nivolumab 3 mg/kg on day 0 of the Nivo-BeGEV or a maximum of 4 cycles Drug: Bendamustine~Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin~Drug: Gemcitabine Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles Other Name: Gemzar~Drug: Vinorelbine Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine
Study: NCT03418805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advil Ibuprofen table 200 mg
Description: Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motrin IB Ibuprofen Tablets 200 mg
Description: Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen CR Tablets 600 mg
Description: Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen CR Tablets 600 mg
Description: Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively
Study: NCT01599897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
Study: NCT03158025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant tablets, over-encapsulated
Description: Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant tablets, over-encapsulated
Description: Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
Study: NCT01599897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ID93 alone
Description: ID93 antigen alone. 3 injections and Days 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ID93 alone
Description: ID93 antigen alone. 3 injections and Days 0, 28, and 56.
Study: NCT01527253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synergistic food basket
Description: A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synergistic food basket
Description: A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
Study: NCT03178292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin 500Mg daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet daily for 5 days
Study: NCT03933605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and palonosetron group
Description: intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron group
Description: intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
Study: NCT04461197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customised foot orthoses
Description: The foot orthoses for group A were custom made using phenolic foam molds of the feet. Separated molds were made of both feet for all the participants. . The insole was made based on a positive mold of plaster with 45 Shore cork materials with horizontal thrusts just proximal to the metatarsal heads, with the intention of correcting the pathological subtalar pronation, with a 3mm bilateral raising of the heel and a bilateral latex metatarsal bar.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: orthotic insole
Description: For group B, a flat insole of polyester resin was made, fitting it to the foot's size.
Study: NCT02872753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACP
Description: Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Meniscectomy
Description: Patients will receive standard arthroscopic meniscectomy
Study: NCT01372761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-433
Description: Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Study: NCT03024606

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text messages focused on smoking cessation and pregnancy
Description: The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
Study: NCT03189329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine hydrochloride
Description: Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levobupivacaine
Description: and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
Study: NCT01667302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by chemotherapy
Description: Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
Study: NCT01161498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Administered by intratumoral injection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 70 grays of radiation administered in 35 fractions over 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 70 grays of radiation administered in 35 fractions over 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered by intravenous infusion
Study: NCT00064714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 (exenatide)
Description: Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 (exenatide)
Description: Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 (exenatide)
Description: Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 (exenatide)
Description: Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab (immunosuppressive)
Description: 2 mg/kg intravenously infused over 30 minutes every month for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab (immunosuppressive)
Description: 2 mg/kg intravenously infused over 30 minutes every month for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab (immunosuppressive)
Description: 2 mg/kg intravenously infused over 30 minutes every month for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab (immunosuppressive)
Description: 2 mg/kg intravenously infused over 30 minutes every month for 12 months
Study: NCT04426461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based therapy
Description: Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy
Description: Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
Study: NCT03996863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband
Description: Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
Study: NCT02710708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP (YAZ, BAY86-5300)
Description: YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
Study: NCT00478738

Intervention type: DRUG
Group type: OTHER
Intervention: GSK961081
Study: NCT02547922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Study: NCT00362778

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Insulin
Description: intravenous continuous insulin infusion for 48 hours
Study: NCT01832467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab-containing chemotherapy
Study: NCT05007678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days